At Merantix we build and scale and invest in machine learning companies. Through our unique incubation platform, seed financing and exceptional teams of entrepreneurs and engineers, we transfer world-leading research into products that will change existing and create new industries.
Ovom redefines how reproductive care is brought to patients by combining modern in-person care with advanced AI-based technology. Catering not just to patients but also to healthcare professionals, we create an ecosystem that allows for increased success rates, improved accessibility, and reduced life disruption for patients.
AI-based process analytics platform to increase productivity and quality in manual shop-floor processes. Processes are captured using computer vision and automatically analysed with a highly flexible AI to identify improvement potential.
Libra is a category-defining generative AI startup specialising in automating litigation workflows and harnessing AI to generate legal claims. In today's world, more people have access to the internet than access to justice. The advent and rapid advancement of large language models offer an unprecedented opportunity not only to automate legal services, but to disrupt the whole industry. That’s why our mission is empowering every claim owner to make full use of their rights. We’re developing a claims drafting factory, which will automatically produce legal claim packages using AI. This will allow us to deliver an easier, more efficient, and higher quality legal service for customers. As a fast-moving venture, we’ve closed three pilots with prominent enterprise customers and raised 1mln EUR in a pre-seed investment from Merantix, Europe’s leading specialist AI Fund. Now we’re growing the team to make our vision a reality. Take a look at our open roles!
Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.
Cambrium's mission is to trigger the next wave of material innovation by harnessing biology’s molecular building blocks. We fundamentally believe that the ability to align economic and environmental incentives makes biology the most important manufacturing technology of the 21st century. Using our molecular design technology, we create novel material building blocks with previously inaccessible functionalities. Our molecules enable innovators to create products that are better for people, and the planet. We are a highly interdisciplinary team of scientists, engineers, designers and entrepreneurs, united by our vision to create materials that matter. Intrepid, vibrant, and purpose-driven we are on a quest to unlock the power of biology, and reinvent materials from the molecular level.